Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset

Antiviral Research

Volumn 163, Issue , 2019, Pages 70-74

  de Wit, Emmie ^a   Feldmann, Friederike ^a   Horne, Eva ^a   Okumura, Atsushi ^b   Cameroni, Elisabetta ^c   Haddock, Elaine ^a   Saturday, Greg ^a   Scott, Dana ^a   Gopal, Robin ^d   Zambon, Maria ^d   Corti, Davide ^c   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Department of Medicine   (United States)

^c A Subsidiary of Vir Biotechnology ^*  (Switzerland)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Common marmoset; LCA60; MERS CoV; Neutralizing monoclonal antibody; Prophylaxis; Treatment

Indexed keywords

LCA 60; MONOCLONAL ANTIBODY; MPE 8; UNCLASSIFIED DRUG; VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREATHING RATE; CALLITHRIX JACCHUS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; INFECTION PREVENTION; MALE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; THORAX RADIOGRAPHY; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CALLITHRIX; CORONAVIRUS INFECTION; DISEASE MODEL; DRUG EFFECT; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LUNG; PATHOLOGY; VIROLOGY;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CALLITHRIX; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; LUNG; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS;

EID: 85060438434     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2019.01.016     Document Type: Article

References (19)

1. Agrawal, A.S., Ying, T., Tao, X., Garron, T., Algaissi, A., Wang, Y., Wang, L., Peng, B.H., Jiang, S., Dimitrov, D.S., Tseng, C.T., Passive transfer of A germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East respiratory syndrome coronavirus infection. Sci. Rep., 6, 2016, 31629.
2. Baseler, L., de Wit, E., Feldmann, H., A comparative review of animal models of Middle East respiratory syndrome coronavirus infection. Vet. Pathol. 53 (2016), 521–531.
3. Bermingham, A., Chand, M.A., Brown, C.S., Aarons, E., Tong, C., Langrish, C., Hoschler, K., Brown, K., Galiano, M., Myers, R., Pebody, R.G., Green, H.K., Boddington, N.L., Gopal, R., Price, N., Newsholme, W., Drosten, C., Fouchier, R.A., Zambon, M., Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill. bulletin europeen sur les maladies transmissibles = European communicable disease bulletin, 17, 2012, 20290.
4. Chan, J.F., Yao, Y., Yeung, M.L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., Cai, J.P., Chu, H., Zhou, J., Chen, H., Qin, C., Yuen, K.Y., Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212 (2015), 1904–1913.
5. Chen, Z., Bao, L., Chen, C., Zou, T., Xue, Y., Li, F., Lv, Q., Gu, S., Gao, X., Cui, S., Wang, J., Qin, C., Jin, Q., Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset. J. Infect. Dis. 215 (2017), 1807–1815.
6. Corman, V.M., Eckerle, I., Bleicker, T., Zaki, A., Landt, O., Eschbach-Bludau, M., van Boheemen, S., Gopal, R., Ballhause, M., Bestebroer, T.M., Muth, D., Muller, M.A., Drexler, J.F., Zambon, M., Osterhaus, A.D., Fouchier, R.M., Drosten, C., Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill. bulletin europeen sur les maladies transmissibles = European communicable disease bulletin, 17, 2012.
7. Corti, D., Bianchi, S., Vanzetta, F., Minola, A., Perez, L., Agatic, G., Guarino, B., Silacci, C., Marcandalli, J., Marsland, B.J., Piralla, A., Percivalle, E., Sallusto, F., Baldanti, F., Lanzavecchia, A., Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501 (2013), 439–443.
8. Corti, D., Passini, N., Lanzavecchia, A., Zambon, M., Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. J. Infect. Public Health 9 (2016), 231–235.
9. Corti, D., Zhao, J., Pedotti, M., Simonelli, L., Agnihothram, S., Fett, C., Fernandez-Rodriguez, B., Foglierini, M., Agatic, G., Vanzetta, F., Gopal, R., Langrish, C.J., Barrett, N.A., Sallusto, F., Baric, R.S., Varani, L., Zambon, M., Perlman, S., Lanzavecchia, A., Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proceedings of the National Academy of Sciences of the United States of America, 112, 2015, 10473–10478.
10. de Wit, E., Feldmann, F., Okumura, A., Horne, E., Haddock, E., Saturday, G., Scott, D., Erlandson, K.J., Stahl, N., Lipsich, L., Kyratsous, C.A., Feldmann, H., Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antivir. Res. 156 (2018), 64–71.
11. de Wit, E., Rasmussen, A.L., Falzarano, D., Bushmaker, T., Feldmann, F., Brining, D.L., Fischer, E.R., Martellaro, C., Okumura, A., Chang, J., Scott, D., Benecke, A.G., Katze, M.G., Feldmann, H., Munster, V.J., Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 110, 2013, 16598–16603.
12. Falzarano, D., de Wit, E., Feldmann, F., Rasmussen, A.L., Okumura, A., Peng, X., Thomas, M.J., van Doremalen, N., Haddock, E., Nagy, L., LaCasse, R., Liu, T., Zhu, J., McLellan, J.S., Scott, D.P., Katze, M.G., Feldmann, H., Munster, V.J., Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog., 10, 2014 e1004250.
13. Falzarano, D., de Wit, E., Rasmussen, A.L., Feldmann, F., Okumura, A., Scott, D.P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., Benecke, A.G., Katze, M.G., Munster, V.J., Feldmann, H., Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19 (2013), 1313–1317.
14. Johnson, R.F., Bagci, U., Keith, L., Tang, X., Mollura, D.J., Zeitlin, L., Qin, J., Huzella, L., Bartos, C.J., Bohorova, N., Bohorov, O., Goodman, C., Kim do, H., Paulty, M.H., Velasco, J., Whaley, K.J., Johnson, J.C., Pettitt, J., Ork, B.L., Solomon, J., Oberlander, N., Zhu, Q., Sun, J., Holbrook, M.R., Olinger, G.G., Baric, R.S., Hensley, L.E., Jahrling, P.B., Marasco, W.A., 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology 490 (2016), 49–58.
15. Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., Wang, Q., Lu, X., Wu, Y., Liu, W., Zhang, B., Yuen, K.Y., Perlman, S., Gao, G.F., Yan, J., A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 25 (2015), 1237–1249.
16. Pascal, K.E., Coleman, C.M., Mujica, A.O., Kamat, V., Badithe, A., Fairhurst, J., Hunt, C., Strein, J., Berrebi, A., Sisk, J.M., Matthews, K.L., Babb, R., Chen, G., Lai, K.M., Huang, T.T., Olson, W., Yancopoulos, G.D., Stahl, N., Frieman, M.B., Kyratsous, C.A., Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proceedings of the National Academy of Sciences of the United States of America, 112, 2015, 8738–8743.
17. Qiu, H., Sun, S., Xiao, H., Feng, J., Guo, Y., Tai, W., Wang, Y., Du, L., Zhao, G., Zhou, Y., Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. Antivir. Res. 132 (2016), 141–148.
18. van Doremalen, N., Falzarano, D., Ying, T., de Wit, E., Bushmaker, T., Feldmann, F., Okumura, A., Wang, Y., Scott, D.P., Hanley, P.W., Feldmann, H., Dimitrov, D.S., Munster, V.J., Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antivir. Res. 143 (2017), 30–37.
19. Zhao, G., He, L., Sun, S., Qiu, H., Tai, W., Chen, J., Li, J., Chen, Y., Guo, Y., Wang, Y., Shang, J., Ji, K., Fan, R., Du, E., Jiang, S., Li, F., Du, L., Zhou, Y., A novel nanobody targeting Middle East respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV. J. Virol., 92, 2018.